MediMabBio announce a new memorandum of understanding (MOU) with PDCline Pharma. This collaboration is aimed to explore the synergy between our MMB101/MFA011 and PDC*line Pharma’s plasmacytoid dendritic cell (PDC) cancer vaccines to revolutionize cancer treatment. Together, our promising drug candidates, targeting TIGIT and other immuno-oncology pathways, would enhance the efficacy of PDC cancer vaccines.

By leveraging PDC*line Pharma’s expertise, we aim to boost the efficacy of our therapies and explore innovative treatment strategies.